Fully automated assays for colorectal cancer, 2/16

Biocartis launched two products on its molecular diagnostics platform Idylla. The first offering, the Idylla ctBRAF Mutation Assay, uses blood plasma as a sample. The assay can potentially act as a substitute for tissue biopsy testing in melanoma and colorectal and lung cancers, as well as conditions such as hairy cell leukemia and histiocytosis. It has a turnaround time of approximately 90 minutes with less than one minute of hands-on time.

The second assay launched is the tissue biopsy Idylla NRAS-BRAF-EGFR S492R Mutation Assay. This assay now allows Biocartis to offer a complete RAS-BRAF analysis that can be performed on a same-day basis. It detects 18 NRAS mutations as well as five BRAF mutations, for which testing is now mandatory in patients with mCRC1.

The assay also detects the so-called EGFR S492R mutation, which is associated with resistance to certain anti-EGFR therapies. Both assays are initially launched as research use only products.

Biocartis , +32 15 632 600